华东医药：控股子公司产品纳入突破性治疗品种名单

Core Viewpoint - The announcement highlights that Huadong Medicine's subsidiary, Zhejiang Daer Biotechnology Co., Ltd., has developed a first-in-class (FIC) long-acting triple-target agonist, DR10624, which has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) for the treatment of severe hypertriglyceridemia [1] Group 1 - Huadong Medicine's subsidiary, Zhejiang Daer Biotechnology Co., Ltd., has independently developed a long-acting triple-target agonist [1] - The triple-target agonist DR10624 targets fibroblast growth factor 21 receptor, glucagon receptor, and glucagon-like peptide-1 receptor [1] - The intended indication for DR10624 is severe hypertriglyceridemia [1]